Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Osmotica Pharmaceuticals stock | $1.94

Learn how to easily invest in Osmotica Pharmaceuticals stock.

Osmotica Pharmaceuticals plc is a biotechnology business based in the US. Osmotica Pharmaceuticals shares (OSMT) are listed on the NASDAQ and all prices are listed in US Dollars. Osmotica Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Osmotica Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OSMT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Osmotica Pharmaceuticals stock price (NASDAQ: OSMT)

Use our graph to track the performance of OSMT stocks over time.

Osmotica Pharmaceuticals shares at a glance

Information last updated 2021-10-16.
Latest market close$1.94
52-week range$1.84 - $6.38
50-day moving average $2.90
200-day moving average $3.15
Wall St. target price$5.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.45

Buy Osmotica Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Osmotica Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Osmotica Pharmaceuticals price performance over time

Historical closes compared with the close of $1.94 from 2021-10-19

1 week (2021-10-13) -3.48%
1 month (2021-09-20) -35.12%
3 months (2021-07-20) -46.11%
6 months (2021-04-20) -36.18%
1 year (2020-10-20) -66.78%
2 years (2019-10-18) -57.27%
3 years (2018-10-19) 9.03
5 years (2016-10-16) N/A

Is Osmotica Pharmaceuticals under- or over-valued?

Valuing Osmotica Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Osmotica Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Osmotica Pharmaceuticals's EBITDA

Osmotica Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $33 million.

The EBITDA is a measure of a Osmotica Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Osmotica Pharmaceuticals financials

Revenue TTM $189.9 million
Operating margin TTM 7.13%
Gross profit TTM $103.4 million
Return on assets TTM 2.12%
Return on equity TTM -77.1%
Profit margin -47.85%
Book value $1.09
Market capitalisation $161.6 million

TTM: trailing 12 months

Shorting Osmotica Pharmaceuticals shares

There are currently 562,916 Osmotica Pharmaceuticals shares held short by investors – that's known as Osmotica Pharmaceuticals's "short interest". This figure is 1% up from 557,454 last month.

There are a few different ways that this level of interest in shorting Osmotica Pharmaceuticals shares can be evaluated.

Osmotica Pharmaceuticals's "short interest ratio" (SIR)

Osmotica Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Osmotica Pharmaceuticals shares currently shorted divided by the average quantity of Osmotica Pharmaceuticals shares traded daily (recently around 131830.44496487). Osmotica Pharmaceuticals's SIR currently stands at 4.27. In other words for every 100,000 Osmotica Pharmaceuticals shares traded daily on the market, roughly 4270 shares are currently held short.

However Osmotica Pharmaceuticals's short interest can also be evaluated against the total number of Osmotica Pharmaceuticals shares, or, against the total number of tradable Osmotica Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Osmotica Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Osmotica Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0185% of the tradable shares (for every 100,000 tradable Osmotica Pharmaceuticals shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Osmotica Pharmaceuticals.

Find out more about how you can short Osmotica Pharmaceuticals stock.

Osmotica Pharmaceuticals share dividends

We're not expecting Osmotica Pharmaceuticals to pay a dividend over the next 12 months.

Osmotica Pharmaceuticals share price volatility

Over the last 12 months, Osmotica Pharmaceuticals's shares have ranged in value from as little as $1.84 up to $6.38. A popular way to gauge a stock's volatility is its "beta".

OSMT.US volatility(beta: 2.25)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Osmotica Pharmaceuticals's is 2.2519. This would suggest that Osmotica Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Osmotica Pharmaceuticals overview

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. .

Frequently asked questions

What percentage of Osmotica Pharmaceuticals is owned by insiders or institutions?
Currently 30.815% of Osmotica Pharmaceuticals shares are held by insiders and 25.29% by institutions.
How many people work for Osmotica Pharmaceuticals?
Latest data suggests 302 work at Osmotica Pharmaceuticals.
When does the fiscal year end for Osmotica Pharmaceuticals?
Osmotica Pharmaceuticals's fiscal year ends in December.
Where is Osmotica Pharmaceuticals based?
Osmotica Pharmaceuticals's address is: 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807
What is Osmotica Pharmaceuticals's ISIN number?
Osmotica Pharmaceuticals's international securities identification number is: IE00BF2HDL56
What is Osmotica Pharmaceuticals's CUSIP number?
Osmotica Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G6S41R101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site